Research progress of oxaliplatin-based regimen for advanced hepatocellular carcinoma / 国际肿瘤学杂志

ABSTRACT

Sorafenib is currently the only systematic molecular targeted drug approved by many coun-tries for the treatment of advanced HCC.But sorafenib limites has survival improvement,patients appear inevi-table disease progression soon.In recent years,Oxaliplatin-based regimens showed promising anti-tumor activi-ty,safety and low toxicities,which provides a new way for treatment of advanced HCC.